for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Green Cross Corp

006280.KS

Latest Trade

235,000.00KRW

Change

-7,500.00(-3.09%)

Volume

94,601

Today's Range

232,000.00

 - 

246,000.00

52 Week Range

232,000.00

 - 

538,000.00

As of on the Korea Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
242,500.00
Open
241,000.00
Volume
94,601
3M AVG Volume
2.13
Today's High
246,000.00
Today's Low
232,000.00
52 Week High
538,000.00
52 Week Low
232,000.00
Shares Out (MIL)
11.41
Market Cap (MIL)
2,734,650.00
Forward P/E
27.84
Dividend (Yield %)
0.64

Next Event

Q4 2021 Green Cross Corp Earnings Release

Latest Developments

More

Mirum Pharmaceuticals & GC Pharma Enter Exclusive Licensing Agreement To Develop And Commercialize Maralixibat For Rare Liver Diseases In South Korea

GC Pharma Receives Japan Approval For Hunterase ICV Injection 15 Mg As A Treatment For Mucopolysaccharidosis Type II

Green Cross to pay cash dividend at 1,250 won/share

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Green Cross Corp

Green Cross Corp is a Korea-based company that mainly engaged in the manufacture and sale of pharmaceutical products. The Company mainly manufactures pharmaceutical products including blood products, general products, vaccines, over the counter (OTC) drugs, diagnostic reagents, placental injections, cell therapies, vaccine fertilized eggs and blood diagnostic products, among others. The Company also provides genome analysis services.

Industry

Biotechnology & Drugs

Contact Info

107, Ihyeon-ro 30beon-gil, Giheung-gu

16924

South Korea

+82.31.2609300

http://www.greencross.com

Executive Leadership

Eun Cheol Huh

Chief Executive Officer, Director

Yeong Ho Kim

Vice President, Director

Yeong Chan Lee

Vice President, Director

Su Hyeon Jung

Managing Director

Yeong Pil Kim

Managing Director

Key Stats

1.78 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, KRW)

2018

1.3K

2019

1.4K

2020

1.5K

2021(E)

1.6K
EPS (KRW)

2018

3,017.000

2019

-319.000

2020

7,101.000

2021(E)

8,271.493
Price To Earnings (TTM)
30.96
Price To Sales (TTM)
1.76
Price To Book (MRQ)
2.27
Price To Cash Flow (TTM)
18.06
Total Debt To Equity (MRQ)
52.77
LT Debt To Equity (MRQ)
29.12
Return on Investment (TTM)
6.65
Return on Equity (TTM)
4.48

Latest News

Latest News

South Korea approves phase II human trial for Green Cross's coronavirus treatment drug

South Korea's Green Cross Corp has received regulatory approval for phase II human clinical trials of its experimental coronavirus plasma treatment drug, the Ministry of Food and Drug Safety said on Thursday.

South Korea's Green Cross seeks phase two trials of COVID-19 plasma drug

South Korea's Green Cross Corp has sought regulatory approval for Phase II trials of an experimental COVID-19 blood plasma treatment drug, the company said on Wednesday, sending its shares up nearly 10%.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up